Sunday September 20, 2020

Pfizer to sweeten Astrazeneca bid before turning hostile

Pfizer is planning to sweeten its bid for British rival AstraZeneca for a second time, people with knowledge of the matter said.

13th May, 2014
{ }

Pfizer is planning to sweeten its bid for British rival AstraZeneca for a second time, people with knowledge of the matter said.

Pfizer and its advisers are crafting a new offer that would increase the value modestly above the current 50 pounds-a-share (about $84) level while bumping the cash portion, said two of the people, who asked not to be identified discussing private information. Pfizer will probably wait until after British government hearings to raise...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 8 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago